Why FDA can’t dis­close the first coro­n­avirus-re­lat­ed drug short­age

Around 10 PM ET last night, the FDA said that it is aware of a drug short­age re­lat­ed to an ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) man­u­fac­tur­er af­fect­ed by the coro­n­avirus, but the agency stopped short of re­veal­ing what drug it is.

“The short­age is due to an is­sue with man­u­fac­tur­ing of an ac­tive phar­ma­ceu­ti­cal in­gre­di­ent used in the drug. It is im­por­tant to note that there are oth­er al­ter­na­tives that can be used by pa­tients. We are work­ing with the man­u­fac­tur­er as well as oth­er man­u­fac­tur­ers to mit­i­gate the short­age. We will do every­thing pos­si­ble to mit­i­gate the short­age,” FDA Com­mis­sion­er Stephen Hahn said in a state­ment.

An FDA spokesper­son al­so con­firmed to Fo­cus that the agency can­not dis­close the drug in short­age “as it is con­fi­den­tial com­mer­cial in­for­ma­tion.”

But she al­so ex­plained why the FDA is in a dif­fi­cult po­si­tion with re­spect to such short­ages and keep­ing the pub­lic in­formed.

“While man­u­fac­tur­ers are legal­ly re­quired to re­port drug sup­ply dis­rup­tions to FDA, they are not re­quired to pro­vide the de­tailed in­for­ma­tion on their sup­ply chain that we have need­ed to mon­i­tor the drug sup­ply since the on­set of the out­break,” the spokesper­son said. “We need the co­op­er­a­tion of the drug com­pa­nies in or­der to ob­tain ac­cu­rate in­for­ma­tion as we proac­tive­ly take steps to mit­i­gate drug short­ages, and com­pa­nies will be less will­ing to pro­vide this vol­un­tary in­for­ma­tion if they can­not trust FDA not to dis­close com­mer­cial con­fi­den­tial in­for­ma­tion such as drug names, com­pa­ny names or ex­act lo­ca­tion of fa­cil­i­ties.”

Al­though it may be dif­fi­cult to as­cer­tain which drug is af­fect­ed, re­cent­ly added drug short­ages to FDA’s list in­clude Al­ler­gan’s treat­ment for com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tions, Avy­caz (cef­tazidime and avibac­tam), My­lan’s blood pres­sure drug pin­dolol 10mg (and Sun Phar­ma­ceu­ti­cal pro­vides the same drug), and Pfiz­er’s chemother­a­py flu­dara­bine phos­phate for in­jec­tion.

Al­ler­gan told Fo­cus in a state­ment: “We are ex­pe­ri­enc­ing an out of stock sit­u­a­tion for AVY­CAZ (cef­tazidime and avibac­tam) for in­jec­tion (2.5g) as we await reg­u­la­to­ry ap­proval on a new third-par­ty man­u­fac­tur­er, which will ul­ti­mate­ly al­low us to con­tin­ue our sup­ply in the U.S. This sit­u­a­tion is not re­lat­ed to any prod­uct or safe­ty is­sue. All cur­rent­ly avail­able AVY­CAZ sup­ply is un­af­fect­ed and not at risk for re­call…To be clear our re­cent drug short­age of AVY­CAZ is not re­lat­ed to the coro­n­avirus.”

The rea­son­ing be­hind My­lan and Sun’s short­ages is list­ed as “short­age of ac­tive in­gre­di­ent,” and My­lan did not re­spond to a re­quest for com­ment.

And for flu­dara­bine, the FDA list­ing says dis­con­tin­u­a­tion of the man­u­fac­ture of the drug is due to API sup­pli­er mar­ket ex­it. The cur­rent sup­ply is ex­pect­ed to be ex­haust­ed next Au­gust.

A Pfiz­er spokesper­son told Fo­cus the short­age “is com­plete­ly un­re­lat­ed and pre-dates the out­break…The ma­jor­i­ty of our fin­ished prod­uct and ac­tive phar­ma­ceu­ti­cal in­gre­di­ent are sourced from coun­tries oth­er than Chi­na. To date, we have not seen a dis­rup­tion to our sup­ply as a re­sult of the virus.”


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

The average level of investment required for a biotech start-up to succeed is increasing every year, elevating the pressure even further on venture capital to make smart financial investments. Financial investment alone, however, does not always guarantee that exciting innovations can be transformed into real businesses that make a meaningful difference to patients.

Beyond just capital

At Astellas Venture Management (AVM) – a wholly-owned venture capital organization within Astellas, headquartered in the San Francisco Bay Area – capital is just one of the ingredients we offer to add value to our biotechnology investments and partnerships. We generally take a strategic investor approach for companies in our invested portfolio, providing access to expertise, technology and/or resources in addition to the injection of finance. An equity investment from AVM can include access to Astellas’ research and development (R&D) capabilities and expertise, and a global network of partner academic institutions and biotechnology companies, to help advance and accelerate the start-up’s innovation.

UP­DAT­ED: Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on a range of clinical trials. But not everyone in R&D is getting a red light.

Vertex says that it’s doing its best to keep working its pipeline strategy, coming up with a plan “to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D sched­ules

Around 100 staffers at Boston area hospitals have now tested positive for Covid-19, spotlighting the growing risk that the pandemic will sideline many of the most essential workers in healthcare as caseloads peak in the US and around the globe. With more than 3,400 deaths, Spain has become the latest country to surpass the official death count attributed to the new coronavirus in China, where the outbreak originated. As of Thursday morning, confirmed global cases had crossed 470,000 and the death count eclipsed 21,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

Two days after Gilead won orphan drug status for remdesivir as a potential treatment for Covid-19, they’re handing it back.

The company was slammed from several sides after Gilead reported that the FDA had come through with the special status, which comes with 7 years of market exclusivity, the waiver of FDA fees and some tax credits as well. Typically, everyone who can get orphan status lands it without much of a fuss, but Democratic presidential candidate Bernie Sanders, Public Citizen and other consumer groups were outraged.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

NIAID director Anthony Fauci has left no doubts that it takes 12 to 18 months to get a new vaccine tested and in commercial use, in the best of circumstances. But in times of a global emergency — like these — maybe there’s another, faster route to follow.

In an SEC filing on Tuesday, Moderna $MRNA staked out a record-setting pathway to getting their mRNA vaccine into the frontline of the healthcare response as early as this fall. The SEC filing notes that CEO Stéphane Bancel told Goldman Sachs that an emergency use approval could allow the vaccine to go to healthcare workers and certain individuals in a matter of months — presumably provided the NIH sees the safety and efficacy data they would need from the Phase I.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.

The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”

The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

Stock buybacks are not to be permitted for companies that will be bailed out in the coronavirus stimulus package, Congressional leaders have signaled. To what degree the biopharma industry has relied on buybacks for earnings growth in recent years, and if the trend continues, are the big questions as scrutiny into the practice heightens and balance sheets weaken with the coronavirus pandemic wreaking havoc on global economies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

A Sin­ga­pore VC rais­es $200M for a new round, but will Covid-19 pre­vent it from rais­ing the rest?

A top Singaporean biotech venture fund is nearly halfway toward its largest ever fund, but in a sign of what could be in store for VCs amid a global economic freeze, said they could face headwinds raising the other half.

Vickers Venture Partners has secured $200 million out of a targeted $500 million for its 6th fund, first announced in early 2018. They’ve given themselves 13 months to complete the financing, Vickers founder Finian Tan told Deal Street Asia, but the financial frost settling amid the Covid-19 pandemic could slow efforts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Strug­gling Unum ex­ecs are ready to con­sid­er a sale, merg­er or any deal that comes its way

Unum $UMRX is working its way through a survival plan of sorts.

After getting hit with a trio of FDA holds in its brief public history and triggering its second pivot to a new lead drug program while laying off 60% of the staff, the troubled penny stock biotech Unum Therapeutics has hatched new plans to secure financial backing while lining up a go-forward strategy for the company.

First, Lincoln Park Capital Fund has agreed to buy up to $25 million of the long-suffering stock, as Unum directs. And the executive team — led by CEO Chuck Wilson — has put everything on the table for consideration: a sale, acquisition, merger, licensing deal, you name it. The ACTR707 program, meanwhile, is being formally wrapped up — their second failed lead program.